Free Trial

Vapotherm Q4 2022 Earnings Report

Vapotherm EPS Results

Actual EPS
-$5.92
Consensus EPS
-$6.32
Beat/Miss
Beat by +$0.40
One Year Ago EPS
N/A

Vapotherm Revenue Results

Actual Revenue
$18.66 million
Expected Revenue
$18.56 million
Beat/Miss
Beat by +$100.00 thousand
YoY Revenue Growth
N/A

Vapotherm Announcement Details

Quarter
Q4 2022
Time
N/A
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Vapotherm Earnings Headlines

Vapotherm, Inc.: Vapotherm Announces Closing of Merger
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Vapotherm Announces Closing of Merger
See More Vapotherm Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vapotherm? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vapotherm and other key companies, straight to your email.

About Vapotherm

Vapotherm (NYSE:VAPO), a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor that provides compressed air necessary to run the precision flow systems in areas of the hospital without access to a wall gas source; aerosol aeroneb adaptor to facilitate delivery of aerosolized solutions; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol solutions for patients; and tracheostomy adaptors that simplifies the connection of the High Velocity Therapy systems to a tracheostomy collar used to wean patients off mechanical ventilation. In addition, the company offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Module, which helps clinicians maintain oxygen levels within a target range. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.

View Vapotherm Profile

More Earnings Resources from MarketBeat

Upcoming Earnings